Read our latest updates & insights

On 9 July 2026, Samsung Bioepis announced it signed a licence option agreement with Proteina, a Korean biotechnology company, to use the results of an R&D project aimed at developing AI-based antibody therpeutics.

The R&D project was launched in October 2025 ...

On 9 July 2026, PR Newswire reported that the FDA has approved Accord BioPharma’s Ennumo™, biosimilar to Amgen’s Neulasta® (pegfilgrastim), for all approved reference indications.

According to the announcement, Accord is now the only company in the US off...

On 9 July 2026, Teva and Polpharma Biologics announced that they entered into an exclusive licensing agreement for the commercialisation of intravenous and subcutaneous formulations of Polpharma Biologics’ PB018, biosimilar to Roche’s Ocrevus® (ocrelizumab).

On 8 July 2026, Shanghai Henlius Biotech announced that the first patient in China has been dosed in its multicentre Phase 1 clinical trial of HLX05-N, biosimilar to Eli Lilly/Merck KGaA’s Erbitux® (cetuximab).

The Phase 1 study, initiated in June 2026, is designed t...

On 8 July 2026, Teva and Samsung Bioepis announced that they have entered an agreement for the commercialisation in Canada of Opuviz®/SB15 (aflibercept), biosimilar to Regeneron/Bayer’s Eylea®.  Under the terms of the licence and commercialisation agreement, Samsung Bioepis...

On 7 July 2026, Celltrion announced that it has successfully secured formulary listings for Vegzelma™, biosimilar to Roche/Genentech’s Avastin® (bevacizumab), with two major pharmacy benefit managers (PBMs) in the US.

Vegzelma™ was listed as a preferred drug on the g...

On 6 July 2026, Novartis and Myricx Bio announced that they have entered into an agreement for the acquisition of Myricx Bio by Novartis.  Myricx Bio is a UK-based biotechnology company developing antibody-drug conjugates (ADCs) using N-myristoyltransferase inhibitor (NMTi)...

On 6 July 2026, Seoul Economic Daily reported that Celltrion has filed with the FDA an amendment to its global Phase 3 clinical trial plan for CT-P51, biosimilar to MSD’s Keytruda® (pembrolizumab).  The amendment reduces the number of trial participants from about 600 to ar...